APELLIS PHARMACEUTICALS INC. - COMMON STOCK
28.78
04-二月-25 16:45:00
15 分钟延时
股票
+0.29
+1.02%
今日范围
28.23 - 29.13
ISIN
N/A
来源
NASDAQ
-
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
01 8月 2024 07:05:00 条件 Nasdaq GlobeNewswire
-
18 7月 2024 07:00:00 条件 Nasdaq GlobeNewswire
-
09 7月 2024 07:00:00 条件 Nasdaq GlobeNewswire
-
28 6月 2024 06:57:12 条件 Nasdaq GlobeNewswire
-
10 6月 2024 07:00:00 条件 Nasdaq GlobeNewswire
-
05 6月 2024 07:00:00 条件 Nasdaq GlobeNewswire
-
24 5月 2024 10:00:00 条件 Nasdaq GlobeNewswire
-
14 5月 2024 08:00:00 条件 Nasdaq GlobeNewswire
-
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
07 5月 2024 07:05:00 条件 Nasdaq GlobeNewswire
-
06 5月 2024 07:00:00 条件 Nasdaq GlobeNewswire
-
01 5月 2024 07:00:00 条件 Nasdaq GlobeNewswire
-
26 4月 2024 07:15:00 条件 Nasdaq GlobeNewswire
-
23 4月 2024 07:00:14 条件 Nasdaq GlobeNewswire
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 4月 2024 16:05:00 条件 Nasdaq GlobeNewswire
-
01 4月 2024 07:00:00 条件 Nasdaq GlobeNewswire
-
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
11 3月 2024 07:00:00 条件 Nasdaq GlobeNewswire
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 3月 2024 16:05:00 条件 Nasdaq GlobeNewswire
-
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
27 2月 2024 07:05:00 条件 Nasdaq GlobeNewswire
-
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
26 2月 2024 07:00:00 条件 Nasdaq GlobeNewswire
-
20 2月 2024 07:00:00 条件 Nasdaq GlobeNewswire